Abstract Library

#4655 A novel nonpeptide drug conjugate (NDC) for the treatment of somatostatin receptor 2-expressing tumours

Introduction: Somatostatin receptor 2 (SST2) is an established target for the treatment of NETs and potentially other solid tumours.

Conference:

Presenting Author:

Authors: Zhao J, Sturchler E, Yang B, Chen M, Tang Y,

Keywords: somatostatin, solid tumour, drug conjugate, internalisation, cytotoxicity,

#4457 Primary mixed hepatocellular carcinoma-neuroendocrine carcinoma: A case report

Introduction: Mixed epithelial neoplasms (MiNENs) are characterised by the coexistence of neuroendocrine and non-neuroendocrine components within a single tumour, each discernible histologically and immunohistochemically, with a minimum tumour proportion of 30%. Primary hepatic MiNENs are exceedingly rare entities.

Conference:

Presenting Author: Tang Y

Authors: Wang Y, Wang R, Yi X, Guo M, Tang Y,

Keywords: pancreatic neuroendocrine tumour, functional, parathyroid hormone related peptide,

#3705 First results from IEO 676 clinical study of PRRT in neuroendocrine tumors – Is there still a space for Y-90-DOTATOC?

Introduction: IEO 676 is a prospective phase II study of Peptide Receptor Radionuclide Therapy (PRRT) with Y-90-DOTATOC in progressive G1, G2, G3, neuroendocrine patients. PRRT has been in use since the late 1990s, with the introduction of 90Y-DOTATOC, which allowed objective responses in 10-30% of treated patients.

Conference:

Presenting Author: Grana C

Authors: Grana C, Papi S, Clerici I, Rocca P, Spada F,

Keywords: PRRT, Y-90-DOTATOC, NET,

#3677 Myelophthisis as an end-stage outcome of rare metastases in neuroendocrine tumors – A dual case report

Introduction: Intra-abdominal Neuroendocrine Tumors (NETs) usually metastasize to regional lymph nodes, liver, and bone. Myelophthisis (MPT) is the destruction of the medullary microenvironment due to the tumoral invasion of the trabecular space, altering normal hematopoiesis; it’s frequently caused by metastasis of breast, prostate, and lung adenocarcinomas, and neuroblastoma. MPT due to NET is an unrecognized phenomenon with few cases reported, almost exclusively in poorly differentiated NETs.

Conference:

Presenting Author:

Authors: González Devia D, Aldana-Gómez L, Segovia Gómez J, Ortiz-Santacruz C, Mejía-Arango M,

Keywords: Neuroendocrine Tumor, Myelophthisis, Colon tumor, Prostate tumor, End-stage,

#3158 Incidence of brain metastases (BMs) and outcomes in patients (pts) with extrapulmonary neuroendocrine neoplasms (EP-NENs)

Introduction: The incidence, management and outcomes of pts with EP-NENs and BMs are unclear.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Kapacee Z, Dawod M, Allison J, Frizziero M, Chakrabarty B,

Keywords: brain metastases, extrapulmonary NENs, radiotherapy, whole brain radiotherapy, survival, grade 3 NEC,